Drug intelligence / Profile preview

ELT-001

Development stage: Preclinical
Lead developer: Elastrin Therapeutics
Administration: Inhalation

Overview

**ELT-001** is a biological product developed by Elastrin Therapeutics for the treatment of **vascular calcification**, a condition associated with endocrinology and metabolic diseases. It is currently in the **preclinical** stage of development, with no disclosed details on its specific mechanism of action, molecular target, or preclinical data.[1][3]

Targets

ELN (Elastin)

Beyond the preview

Go deeper on ELT-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELT-001.

Explore the full profile